{"id":666,"date":"2021-11-20T21:32:00","date_gmt":"2021-11-20T21:32:00","guid":{"rendered":"https:\/\/vicare.org.ar\/?p=2050"},"modified":"2021-11-20T21:32:00","modified_gmt":"2021-11-20T21:32:00","slug":"investigacion-sobre-el-cancer-de-rinon","status":"publish","type":"post","link":"https:\/\/vicare.org.ar\/eng\/investigacion-sobre-el-cancer-de-rinon\/","title":{"rendered":"Investigaci\u00f3n sobre el c\u00e1ncer de ri\u00f1\u00f3n"},"content":{"rendered":"<ul>\n<li><a href=\"https:\/\/www.cancer.gov\/espanol\/noticias\/temas-y-relatos-blog\/2021\/fda-belzutifan-tumores-vhl\">Se aprob\u00f3 el belzutif\u00e1n para tratar tumores relacionados con la enfermedad hereditaria de Von Hippel-Lindau<\/a>Publicaci\u00f3n:\u00a0<time datetime=\"2021-11-12T12:00:00Z\">12 de noviembre de 2021<\/time>\n<p>La FDA aprob\u00f3 el belzutif\u00e1n (Welireg) para tratar a adultos con enfermedad de Von Hippel-Lindau (VHL) que tienen tumores de ri\u00f1\u00f3n, enc\u00e9falo, sistema nervioso o p\u00e1ncreas. Al achicar los tumores, el medicamento tal vez ayude a que estos pacientes eviten o retrasen la cirug\u00eda.<\/p>\n<\/li>\n<li><a href=\"https:\/\/www.cancer.gov\/espanol\/noticias\/temas-y-relatos-blog\/2021\/carcinoma-celulas-renales-papilar-cabozantinib\">La terapia dirigida con cabozantinib disminuye la progresi\u00f3n de un c\u00e1ncer de ri\u00f1\u00f3n poco com\u00fan<\/a>Publicaci\u00f3n:\u00a0<time datetime=\"2021-04-30T12:00:00Z\">30 de abril de 2021<\/time>\n<p>El cabozantinib (Cabometyx) es un tratamiento inicial eficaz para las personas con carcinoma de c\u00e9lulas renales papilar (CCRP) metast\u00e1sico, un tipo de c\u00e1ncer de ri\u00f1\u00f3n poco com\u00fan. En un estudio cl\u00ednico se demostr\u00f3 que el medicamento fue m\u00e1s eficaz que el tratamiento est\u00e1ndar actual.<\/p>\n<\/li>\n<li><a href=\"https:\/\/www.cancer.gov\/espanol\/noticias\/temas-y-relatos-blog\/2020\/biopsia-liquida-cancer-rinon-encefalo\">Se usan biopsias l\u00edquidas para detectar el c\u00e1ncer de ri\u00f1\u00f3n en estadio temprano y el c\u00e1ncer de enc\u00e9falo<\/a>Publicaci\u00f3n:\u00a0<time datetime=\"2020-09-24T12:00:00Z\">24 de septiembre de 2020<\/time>\n<p>Los resultados de dos estudios indicaron que mediante el uso de una biopsia l\u00edquida para analizar ADN en la sangre se detect\u00f3 con precisi\u00f3n el c\u00e1ncer de ri\u00f1\u00f3n en los estadios m\u00e1s tempranos y en los estadios m\u00e1s avanzados. Tambi\u00e9n se identificaron y clasificaron distintos tipos de tumores de enc\u00e9falo.<\/p>\n<\/li>\n<li><a href=\"https:\/\/www.cancer.gov\/espanol\/noticias\/temas-y-relatos-blog\/2019\/cancer-renal-inmunoterapia-terapia-dirigida-combinacion\">Las combinaciones de terapia dirigida e inmunoterapia son efectivas para c\u00e1ncer avanzado de ri\u00f1\u00f3n<\/a>Publicaci\u00f3n:\u00a0<time datetime=\"2019-04-24T12:00:00Z\">24 de abril de 2019<\/time>\n<p>En dos estudios cl\u00ednicos, tratamientos de combinaci\u00f3n que incluyeron un inhibidor de punto de control y axitinib (Inlyta) produjeron mejores resultados para pacientes con c\u00e1ncer avanzado de ri\u00f1\u00f3n que el tratamiento con sunitinib (Sutent), la terapia convencional inicial.<\/p>\n<\/li>\n<li><a href=\"https:\/\/www.cancer.gov\/espanol\/noticias\/temas-y-relatos-blog\/2018\/renal-cancer-fda-nivolumab-ipilimumab-primera-linea\">FDA aprueba la combinaci\u00f3n de nivolumab e ipilimumab para c\u00e1ncer avanzado de ri\u00f1\u00f3n<\/a>Publicaci\u00f3n:\u00a0<time datetime=\"2018-06-19T12:00:00Z\">19 de junio de 2018<\/time>\n<p>FDA ha aprobado la combinaci\u00f3n de dos f\u00e1rmacos de inmunoterapia, nivolumab (Opdivo) e ipilimumab (Yervoy), como tratamiento inicial para algunos pacientes con c\u00e1ncer avanzado de ri\u00f1\u00f3n. Ent\u00e9rese de c\u00f3mo esta aprobaci\u00f3n afectar\u00e1 la atenci\u00f3n de pacientes.<\/p>\n<\/li>\n<li><a href=\"https:\/\/www.cancer.gov\/espanol\/noticias\/temas-y-relatos-blog\/2018\/cabozantinib-fda-primera-linea-rinon\">La aprobaci\u00f3n de cabozantinib ampl\u00eda las opciones de tratamiento para el c\u00e1ncer avanzado de ri\u00f1\u00f3n<\/a>Publicaci\u00f3n:\u00a0<time datetime=\"2018-04-06T12:00:00Z\">6 de abril de 2018<\/time>\n<p>La Administraci\u00f3n de Alimentos y Medicamentos ha aprobado cabozantinib (Cabometyx\u00ae) como tratamiento inicial para pacientes con carcinoma avanzado de c\u00e9lulas renales, el tipo m\u00e1s com\u00fan de c\u00e1ncer de ri\u00f1\u00f3n.<\/p>\n<\/li>\n<li><a href=\"https:\/\/www.cancer.gov\/espanol\/noticias\/temas-y-relatos-blog\/2016\/fda-cabozantinib-lenvatinib-renal\">Dos nuevas terapias aprobadas por la FDA para c\u00e1ncer renal avanzado<\/a>Publicaci\u00f3n:\u00a0<time datetime=\"2016-06-22T12:00:00Z\">22 de junio de 2016<\/time>\n<p>La FDA ha aprobado dos f\u00e1rmacos, cabozantinib y lenvatinib, para pacientes cuyo cancer renal avanzado ha evolucionado despu\u00e9s de tratamiento con terapias antiangiog\u00e9nicas.<\/p>\n<\/li>\n<\/ul>\n<p>Fuente: <a href=\"https:\/\/www.cancer.gov\/espanol\/tipos\/rinon\/investigacion\" target=\"_blank\" rel=\"noopener\">https:\/\/www.cancer.gov\/espanol\/tipos\/rinon\/investigacion<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Se aprob\u00f3 el belzutif\u00e1n para tratar tumores relacionados con la enfermedad hereditaria de Von Hippel-LindauPublicaci\u00f3n:\u00a012 de noviembre de 2021 La [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":667,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[7],"tags":[26,10,24,14,11,27,25],"class_list":["post-666","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-espacio-informativo","tag-cancer","tag-cancer-de-rinon-2","tag-cancer-de-vejiga-2","tag-gador","tag-merck","tag-oncologico","tag-vicare"],"_links":{"self":[{"href":"https:\/\/vicare.org.ar\/eng\/wp-json\/wp\/v2\/posts\/666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vicare.org.ar\/eng\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vicare.org.ar\/eng\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vicare.org.ar\/eng\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/vicare.org.ar\/eng\/wp-json\/wp\/v2\/comments?post=666"}],"version-history":[{"count":0,"href":"https:\/\/vicare.org.ar\/eng\/wp-json\/wp\/v2\/posts\/666\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vicare.org.ar\/eng\/wp-json\/wp\/v2\/media\/667"}],"wp:attachment":[{"href":"https:\/\/vicare.org.ar\/eng\/wp-json\/wp\/v2\/media?parent=666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vicare.org.ar\/eng\/wp-json\/wp\/v2\/categories?post=666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vicare.org.ar\/eng\/wp-json\/wp\/v2\/tags?post=666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}